Pravastatin at 10 mg/day does not decrease plasma levels of either amyloid-β (Aβ) 40 or Aβ 42 in humans

Kazuhiro Ishii, Takahiko Tokuda, Teruhiko Matsushima, Fuyuki Miya, Shin'ichi Shoji, Shu Ichi Ikeda, Akira Tamaoka

Research output: Contribution to journalArticlepeer-review

46 Citations (Scopus)


It has been assumed that statins work as a preventative drug for Alzheimer's disease (AD). Although some epidemiological observations raise doubts to the effectiveness of statins for AD, many in vitro and clinical studies insist on the effectiveness of statins decreasing amyloid-β (Aβ) levels in medium or blood. To explore the effect of pravastatin on Aβ production, we followed the longitudinal plasma levels of both Aβ 40 and Aβ 42 during the allocation of pravastatin in 46 patients with hyperlipidemia. We found no correlation between plasma cholesterol levels or the decreasing values of total cholesterol and those of Aβ 40 or Aβ 42. Patients having Apolipoprotein E4 (ApoE4) had higher low-density lipoprotein levels and lower Aβ 40 levels in plasma, suggesting ApoE4 seems to influence plasma Aβ levels via cholesterol metabolism.

Original languageEnglish
Pages (from-to)161-164
Number of pages4
JournalNeuroscience Letters
Issue number3
Publication statusPublished - 2003 Oct 30
Externally publishedYes


  • Alzheimer's disease
  • Amyloid-β (Aβ) 40
  • Aβ 42
  • Cholesterol
  • Pravastatin

ASJC Scopus subject areas

  • General Neuroscience


Dive into the research topics of 'Pravastatin at 10 mg/day does not decrease plasma levels of either amyloid-β (Aβ) 40 or Aβ 42 in humans'. Together they form a unique fingerprint.

Cite this